Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD

Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD

One of the main problems in oncology is the development of drugs that cause the death of cancer cells without damaging normal cells. Another key problem to be solved is to suppress the drug resistance of cancer cells. The third important issue is to provide effective penetration of drug molecules to...

Full description

Bibliographic Details
Main Authors: Roman Fadeev, Alexey Chekanov, Marina Solovieva, Olga Bezborodova, Elena Nemtsova, Nadezda Dolgikh, Irina Fadeeva, Anatoly Senotov, Margarita Kobyakova, Yana Evstratova, Raisa Yakubovskaya, Vladimir Akatov
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:International Journal of Molecular Sciences
Subjects:
TRAIL/Apo2L
multicellular TRAIL-resistance
sorafenib
tumor-penetrating peptide iRGD
HT-1080 human fibrosarcoma cells
Online Access:https://www.mdpi.com/1422-0067/20/3/525

Internet

https://www.mdpi.com/1422-0067/20/3/525

Similar Items